INTRODUCTION
MicroRNAs (miRNAs) are endogenous small non-coding RNAs that regulate gene expression post transcriptionally by binding of target mRNAs to regulate their stability or translation.
1 MiRNAs are transcribed as long primary miRNA (pri-miRNA) transcripts that are processed into precursor hairpin intermediates (pre-miRNA) and then to 19-27 nucleotide mature miRNAs through a complex and highly regulated biogenesis process. The mature miRNA binds to semi-complementary bases in the target mRNA, usually in the 3'-untranslated region (3'-UTR) but also occasionally in 5' untranslated region (5'UTR) 2,3 or coding regions of target mRNAs. 4 Each miRNA is believed to target multiple mRNAs, thereby providing a critical post-transcriptional mechanism to regulate diverse cellular functions including development, proliferation, and apoptosis.
5
Accumulating evidence suggests that mutation of miRNAs may contribute to the pathogenesis of cancer. Genes encoding miRNAs are often located in fragile sites and regions of chromosomal aberrations in cancer. 6 A survey of miRNA genes by array-based comparative genome hybridization in breast, ovarian, and melanoma samples showed that regions containing miRNAs were often targeted for amplification, loss of heterozygosity, and structural breakpoints in tumors. 7 In chronic lymphocytic leukemia (CLL), for example, deletion of chromosome 13q14, the most common cytogenetic abnormality in CLL, results in loss of miR-16-1 and miR-15a, which are negative regulators of bcl2. 8 Interestingly, no somatic single nucleotide mutation of miRNA genes in primary human cancer has been reported to date.
MiRNA expression profiling has identified deregulated miRNAs in many different types of cancer. 9 In leukemia, expression profiles of just 4 miRNAs can reliably distinguish between acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). 10 In AML, miRNA signatures can also distinguish between cytogenetic subtypes [11] [12] [13] [14] and even molecular subtypes (presence of NPM1, CEBPA or FLT3 mutations).
12
MiRNA expression patterns may have
For personal use only. on June 10, 2017. by guest www.bloodjournal.org From prognostic significance in cancer. For example, in cytogenetically normal high-risk AML patients, the expression pattern of 12 specific miRNAs is associated with improved survival. 15 MiRNA expression profiling, while providing important information, does not interrogate all known (or predicted) miRNAs and is unable to detect mutations in miRNAs. Herein, we used next generation sequencing technologies to comprehensively assess miRNA expression, miRNA mutations, and miRNA binding site mutations in a patient with AML. RNA sequencing showed that 472 miRNAs were expressed in the AML sample (including 7 novel miRNAs), some of which were differentially expressed compared with normal CD34+ cells. Massive parallel sequencing of all known miRNA genes revealed several novel germline polymorphisms but no acquired mutations. Finally, we analyzed the previously generated whole-genome sequencing data for this AML genome 16 to detect somatic mutations in the untranslated region of all coding genes. A single mutation in the putative tumor suppressor gene TNFAIP2 was detected. We provide evidence that this mutation generates a new miRNA binding site that leads to translational repression of TNFAIP2. To the best of our knowledge, this represents the first description of somatic mutation affecting gene expression through the generation of a new miRNA binding site.
METHODS

Human Subjects
All AML samples were obtained from a study at Washington University to identify genetic factors contributing to AML initiation and progression. In addition, bone marrow samples were obtained from healthy volunteers. Approval was obtained from the Washington University institutional review board for these studies. After obtaining written informed consent in accordance with the Declaration of Helsinki, a bone marrow sample was obtained. In addition, for patients with AML, a 6-mm punch biopsy of skin was obtained for analysis of unaffected somatic cells.
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MiRNA sequencing
RNA was prepared from bone marrow sample from patient 933124 (AML1) 16 (greater than 95% blasts) using Trizol reagent (Invitrogen). CD34+ cells were isolated from the bone marrow of 5 healthy donors using MACS sorting according to the manufacturer's instructions (Miltenyi Biotec), and RNA prepared using Trizol reagent. Small RNA libraries were constructed from 508 ng of CD34+ cell and 789 ng of AML1 bone marrow RNA using the SOLiD TM small RNA expression kit according to the manufacturer's instructions (Applied Biosystems). The amplified cDNAs were resolved on a 6% DNA Retardation Gel (Invitrogen), and cDNA fragments between 104-120 bp, corresponding to miRNAs between 19 and 26 nucleotides in length were excised.
DNA was eluted from the gel slices by incubation overnight in 400 mM NaCl and precipitated by adding 2.5 volumes of 100% ethanol and 15µg GlycoBlue (Ambion), incubating at -20º C for 4 hours, and centrifuging at 12,000 x g for 30 minutes at 4º C. The resulting libraries were amplified onto beads using emulsion PCR, deposited on slides, and sequenced using the SOLiD v 2 sequencing system (Applied Biosystems). Post run filters found 27.9 and 20.7 million AML1 and CD34 pooled beads, respectively. All sequence data were deposited in the NCBI's short read archive (study accession number: SRP002249).
Novel miRNA discovery
SOLiD reads were mapped to the Hs36 reference sequence using Maq 17 in colorspace mode.
The resulting read alignments were clustered and assessed for coverage using RefCov, which provides a topologic representation of alignments at each nucleotide of a cluster and statistics to represent the depth of maximal alignment. Some 72,433 clusters in AML1 and 34,320 clusters in CD34 cells had at least 10 supporting reads in the SOLiD data; the read depth per cluster ranged from 302 to 626,334 for AML1 clusters and from 161 to 500,220 for CD34 clusters. The top 1,000 clusters (by coverage) in both AML1 and CD34 cells were combined together (yielding For personal use only. on June 10, 2017. by guest www.bloodjournal.org From 1,488 unique clusters), and their RNA secondary structure analyzed using an in-house validation tool (miRNAViewer). In brief, this tool simultaneously provides cluster information (cluster genome location, sequence, zenith depth, annotation of genome location), MFold-based secondary structure predictions, 18 and RefCov alignment coverage maps. In addition, the tool allows for flexible adjustment of the candidate precursor location to allow for manual changes to the cluster sequence genomic window based on the initial folding and read alignment results.
Criteria used to identify novel miRNAs are detailed in the Results section. Conservation scores for individual bases were determined using phylo-HMM and the UCSC Genome Browser Database, as described previously. 19 For miRNA clusters, conservation scores were calculated as the mean of positional scores across the cluster region.
Expression profiling of known miRNAs
The hairpin, mature, and mature* sequences for known human miRNA genes were downloaded from MiRBase release 13.0. [20] [21] [22] To determine relative expression of known miRNAs, SOLiD reads were mapped to the human hairpin sequences using SHRiMP v1.2. 23 Alignments were filtered to remove multiple/ambiguous read placements and hits with probcalc p-value >1.0e-06.
The filtered alignments were compared to the hairpin-based coordinates of known mature, mature*, mature 5P, and mature 3P sequences to obtain digital read counts of miRNA expression for each sequence.
Expression of known miRNAs in the AML1 and CD34 cells samples was also assessed using Agilent miRNA microarrays. Total RNA (100 ng) was labeled using the Agilent miRNA Microarray System version 1.5 according to the manufacturer's instructions (Agilent), and hybridized to Agilent 'pre-release' human miRNA arrays (array design ID 018077), containing probes to all miRNAs in miRBase v10.0. Microarrays were scanned with an Agilent DNA Microarray Scanner. Images were gridded and analyzed using Agilent feature extraction software version 9.5.3.1. Data were normalized to the 75% median intensity of each array, and
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Real-time reverse transcription-polymerase chain reaction (RT-PCR) of miRNAs
Total RNA was reverse transcribed using the TaqMan® MicroRNA Reverse Transcript Kit per manufacturer's instructions (Applied Biosystems). Real time PCR for the indicated miRNA and RNU48 (as a control) was performed using the relevant TaqMan® MicroRNAassay (Applied Biosystems).
sequencing of miRNA genes
Genomic coordinates for all 695 known human miRNA genes at the time this study was initiated were obtained from miRBase (release 12.0). PCR amplicons were designed to sequence approximately 200 bp of sequence flanking each miRNA precursor. These were later supplemented with 18 amplicons from low-coverage regions, bringing the total to 1,396 amplicons (average size: 315 bp). PCR reactions were performed separately to produce 1,396 products from whole genome amplified (WGA) tumor genomic DNA of patient AML1. All PCR products were pooled and sequenced using the 454-XLR platform (Roche). Since sequence coverage was variable, the sequencing was repeated, this time after normalizing amplicon input.
The 454 sequence data were combined into a single SFF file (using the sfffile utility) that contained 288,862 reads totaling 72.3 Mbp, with an average read length of 250 bp.
sequence analysis and variant detection
Read sequences and quality values were extracted using the sffinfo program (Roche), and aligned to the Hs36 reference sequence using Blat (v32x1). We provided a soft-masked reference sequence and the "mask=lower" parameter, so that repetitive regions were excluded For personal use only. on June 10, 2017. by guest www.bloodjournal.org From during seeding of alignments but included when extending alignments. The resulting BLAT alignments were screened for single nucleotide variants (SNVs) and insertion/deletions (indels) using VarScan.
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Reads with alignment identity of <95%, alignment scores of <50, or two possible locations with the highest alignment score were discarded. To avoid artifacts from regions homologous to multiplex identifier (MID) primer tails, we excluded variants called within 10 bp of the start or end of the read. To call a variant, we required >10x sequence coverage, with >25% of reads showing the variant allele, and an average base quality of 15.
Variant cross-validation with AML1 whole-genome sequencing data
We examined Illumina SNV data from the previously published whole-genome sequencing of AML1.
16 Depth-filtered SNV calls from the tumor sample and unfiltered SNV calls from the matched skin sample were obtained from Maq v0.6.5. 17 The read counts supporting each allele in tumor (~40x coverage) and skin (matched control; ~18x coverage) samples were extracted from Maq map files using the internally developed snp-metrics program. Known human sequence variants were downloaded from public database dbSNP build 129. 25 These were parsed to remove entries that were ambiguously mapped, spanned multiple bases, had three or more alleles, or were classified as a variant type other than SNP.
Variant detection and validation in the untranslated regions of coding genes in AML1
The previously published whole genome sequencing data was analyzed for sequence variants in the untranslated regions of all coding genes. A total of 29,166 coding genes were analyzed based on the Ensembl and NCBI/Genbank databases as of August 27, 2007. All sequence variants identified in the whole genome sequencing were independently validated by 454-based sequencing as described previously. 16 The TNFAIP2 3'UTR mutation was screened in 187 other AML patient samples using the same approach. GCTCGAAATCTTACGCAAATA-3') were generated as previously described.
28,29
Virus production and infections were carried out according to established methods. 29 Following infection, cells were selected with 1 μg/ml puromycin, and DICER1 protein expression assessed by immunoblotting using rabbit polyclonal anti-DICER1 H212 (sc-30226, Santa Cruz Biotechnology, Inc., Santa Cruz, CA). 30 Immunoblotting for GAPDH using a mouse monoclonal anti-GAPDH (NB615, Novus Biologicals, Littleton, CO) was used as a protein loading control.
miR-223 and miR-181b overexpression
A miR-223 'mini-gene' containing the pre-miR-223 hairpin sequence and ~200 bp of flanking sequence (total 527 bp) was PCR-amplified using the following primers: 5'-CTTTACCTGCTTATCTTCAGGATCTCT-3' and 5'-CGTACGCGCCCCCATCAGCACTCT-3'.
The resulting amplicons was cloned downstream of the green fluorescent protein (GFP) gene in Luciferase assays using psiCheck2 TNFAIP2 3'-UTR sensor plasmids
Oligonucleotides corresponding to the region of the 3'-UTR of TNFAIP2 shown in Figure 6A were synthesized containing the germline or mutated sequence, and the annealed oligonucleotides were cloned into the psiCheck2 vector (Promega) downstream of Renilla luciferase. The psiCheck2 vector also contains Firefly luciferase for normalization. For luciferase assays, the indicated psiCheck2-3'UTR vectors were transfected into 293T cells, HS-5 and KLE cell lines using DharmaFect Duo or into K562 cells by nucleofection. Luciferase activity was determined after 48 hours using the Dual-Glo substrate system (Promega) and a Beckman Coulter LD400 luminometer. Data are presented as the ratio of experimental (Renilla) luciferase to control (Firefly) luciferase.
Statistical analyses
Significance was determined using Prism software (Graphpad) to perform two-tailed Student t tests assuming equal variance. All data are presented as the mean ± SEM.
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RESULTS
Case Presentation
We previously reported the sequence of the cancer genome for a patient with AML (AML1) 16 . In brief, a female in her 50s with no significant past medical history presented with FAB M1 AML. Routine cytogenetics revealed a normal 46 XX karyotype, and high-resolution comparative genomic hybridization (CGH) studies revealed no somatic copy number alterations at a resolution of ~5kb. The patient achieved a complete remission with standard chemotherapy but relapsed at 11 months and expired 23 months after the initial diagnosis. Whole genome sequencing identified a total of 10 genic, non-synonymous somatic mutations, including mutations in NPM1 and FLT3.
Identification of novel miRNAs
Massively-parallel sequencing of small RNAs isolated from the myeloblasts of AML1 was performed using the ABI SOLiD TM sequencing platform. As a control, we also analyzed pooled RNA isolated from CD34+ bone marrow cells of 5 healthy volunteers (CD34). In each case, cDNA was size fractionated (corresponding to RNAs of 19-26 nucleotides in length) to enrich for miRNAs prior to sequencing. A total of 28 million sequence reads from AML1 and 20 million reads from CD34 were obtained. These sequences were aligned in color space to the human genome reference sequence (NCBI36) using the Maq aligner. Reads that did not map to the human genome were excluded from further analysis. In the AML1 sample, we identified 4 million unique genomic clusters from 12.7 million mapped reads. In the CD34 sample, we identified 1.7 million unique clusters from 6.4 million mapped reads ( Figure 1A ).
We selected the top 1000 clusters from AML1 and CD34 (a combined total of 1488) to screen for potential novel miRNAs. Only 171 of the clusters represented known genes, including 79 named miRNAs and 67 snoRNAs ( Figure 1A ). The remaining unannotated clusters were manually reviewed to identify novel miRNAs. An in-house program (miRNAViewer) was
For personal use only. on June 10, 2017. by guest www.bloodjournal.org From developed to view the RNA secondary structure of cluster sequences in 50, 100, 150, and 200 bp windows. The following criteria were used to identify miRNAs: 1) predicted RNA secondary structure with a free energy (∆G) of less than -15 kcal; 2) alignment of sequencing reads to one of the hairpin arms; and 3) a combined read count of 50 or more between AML1 and CD34.
Applying these criteria in a blinded fashion, 78 of 79 known miRNAs in the top 1488 clusters were correctly identified as miRNAs. Among the top 1488 clusters, a total of 7 novel putative miRNAs were identified (Supplemental Table 1 ). Consistent with the rate of star species reported for known miRNAs, a star species was detected for 2 of 7 (29%) novel miRNAs (Supplemental Table 1 ). The highest expressed novel miRNA in both AML1 and CD34 cells was s-cluster-100, representing 0.15% and 0.35% of all miRNA sequences, respectively ( Figure   1B ). Several novel miRNAs, were differentially expressed in AML1 when compared to CD34.
Assessment of miRNA expression using deep sequencing
To assess miRNA expression, the sequence reads were aligned to hairpin sequences present in the miRNA Sanger database version 13 (795 known human miRNAs) and hairpin sequences from the 7 novel miRNAs described above. Expression of 421 and 384 known miRNAs were detected in AML1 and CD34, respectively (Supplemental Table 2 ). MiR-233 was the most highly expressed miRNA in both AML1 and CD34 ( Figure 2A ). Remarkably, it represented 49.66% of all miRNA reads in AML1. We compared relative expression levels between AML1 and CD34 cells among miRNAs with read counts of 50 or higher ( Figure 2B and Supplemental Table 2 ). The most overexpressed miRNA in AML1 was miR-362-3p, which was increased 4.92 fold, compared with CD34 cells. The most under-expressed miRNA in AML1 was miR-25, which was decreased nearly 60-fold compared with CD34.
To compare our deep sequencing approach for miRNA expression with traditional arraybased methods, we hybridized the AML1 and CD34 RNAs on Agilent miRNA arrays. In general, the correlation of expression levels between platforms was highly significant (r²= 0.4372 for Figure 3B ). At the standard input RNA (4 ng), the observed cycle number (<16) was outside the dynamic range of this assay.
Indeed, serial dilution of the AML1 RNA sample was required to fully appreciate the very high expression of miR-223.
To determine if extremely high miR-223 expression is a consistent feature of AML, we performed real time RT-PCR for miR-223 (after appropriate sample dilution) in an additional 26 AML samples ( Figure 3C ) and in CD34+ bone marrow cells from 8 healthy donors. In each case, miR-223 expression was normalized to RNU48 (SNORD48); a previous study showed that expression of this snoRNAs varied minimally in human AML samples.
12 Compared with normal CD34+ bone marrow cells, miR-223 expression in AML1 was increased 6.8-fold.
However, increased miR-223 expression was not a common feature of AML. Only 5 of 26 additional AML samples had relative miR-223 expression that was 2 standard deviations above that seen in normal CD34+ bone marrow cells.
MiRNA isomiR patterns are similar in AML1 and normal CD34 cells
Previous miRNA sequencing studies have identified variants of miRNAs (termed isomiRs) that differ in mature miRNA length or less commonly in nucleotide sequence and are thought to arise from variable miRNA processing or RNA editing, respectively [32] [33] [34] [35] . IsomiRs were detected for all abundantly expressed miRNAs. Consistent with previous reports 32, 34, 35 , the majority of isomiRs represent truncations or extensions at the 5'-or 3'-ends of the mature miRNA ( Figure 4A ). Nucleotide substitutions were largely restricted to the last 10 nucleotides at the 3' end of the miRNAs and do not conform to established RNA editing mechanisms in the majority of cases. Though the functional significance of isomiRs is unclear, we asked whether the pattern of isomiRs differed between AML1 and CD34 cells. We identified the isomiRs for all miRNAs that had at least 1000 read counts between the AML1 and CD34 samples and determined the percentage of each isomiR relative to the total sequence reads for that miRNA.
Interestingly, the pattern of isomiR expression was nearly identical in the leukemic and normal CD34 cell samples ( Figure 4B ). These data suggest that, at least for the highest expressed miRNAs, the pattern of isomiRs is not altered during leukemic transformation.
Identification of genetic variants in miRNA genes in AML1 by next generation sequencing
We used the Roche/454 Titanium pyrosequencing platform to sequence all 695 miRNA genes in the Sanger miRNA database at the time this project was initiated (version 12.0). We miRNA genes, 660 (95.0%) had at least one supporting sequence read and 90% of the bases had at least 40X sequence coverage.
We applied the VarScan 36 tool to identify sequence variants in the 454 data. A total of were previously annotated variants in dbSNP ( Figure 5 ). To validate the remaining 40 SNVs and determine their somatic status, we used the previously reported whole-genome sequencing data for the leukemic and normal (skin) genomes of this patient. 16 Adequate sequence coverage of the genome was available for 33 of these SNVs. Twenty were not confirmed and likely represent sequencing artifacts. The remaining 13 SNVs were present in both the leukemic and normal genomes of this patient, suggesting that they represent novel germline single nucleotide polymorphisms (SNPs). Interestingly, three of these novel SNPs were located in the precursor miRNA (Table 1 ). In addition to the SNVs, a single germline deletion in hsa-miR-620 was detected by both sequencing platforms (Table 1) . Of note, no somatic mutations of miRNA genes were detected in the leukemic genome of this patient.
Identification of a somatic mutation in the 3'UTR region of TNFAIP2
Mutations in coding genes might generate or destroy miRNA binding sites. The TNFAIP2 3'-UTR mutation results in decreased expression of a reporter gene in a miRNA dependent fashion A number of bioinformatic tools (see Methods) were used to determine whether the TNFAIP2 3'-UTR mutation altered an existing, or generated a new, miRNA binding site. No miRNA binding sites were identified near the mutated site in the germline TNFAIP2 3'-UTR.
However, the TNFAIP2 mutation was predicted to generate imperfect binding sites for miR-223 and miR-181b ( Figure 6A ). To directly test the effect on expression, the germline or mutant TNFAIP2 3'-UTR (40 bp flanking the mutation) were cloned downstream of the renilla luciferase reporter gene. In both K562 and 293T cells, the mutant TNFAIP2 sequence resulted in significant inhibition of reporter gene expression ( Figure 6B ). Of note, K562 cells have relatively high miR-223 expression and low miR-181b expression, whereas 293T have relatively high miR-181b and low miR-223 expression ( Figure 6C) . Surprisingly a similar decrease in renilla luciferase expression was seen with the mutant TNFAIP2 in the HS-5 cell line ( Figure 6B ), a human bone marrow stromal cell line that has low levels of expression of both miR-223 and miR-181b ( Figure 6C ). We next assessed the effect of the enforced expression of miR-223 or miR-181b on translation repression by the mutant TNFAIP2 3'-UTR. We were unable to consistently achieve miR-223 or miR-181b overexpression in HS-5 cells. Instead, we transiently transfected 293T or K562 cells with expression vectors for miR-181b or miR-223, respectively; expression levels similar to that seen in normal CD34+ cells were achieved ( Figure 6C ).
Enforced expression of miR-223 in 293T cells did not result in translation repression by the mutant or germline TNFAIP2 3'-UTR ( Figure 6D ). Interestingly, expression of miR-181b in K562 1 7 cells, though having no effect on the translation of constructs with the mutant TNFAIP2-3'-UTR, resulted in significant translational repression by the germline TNFAIP2 3'-UTR. Overall these results suggest that miR-223 and miR-181b do not mediate the translational repression of mutant TNFAIP2 3'-UTR.
To address whether the observed translational repression by the mutant TNFAIP2 3'-UTR was dependent on miRNAs, we developed a cell line with constitutive knock-down of Dicer. In brief, the human endometrial cancer cell line KLE was transduced with lentivirus expressing RNAi against Dicer (shDcrA) or, as a control, red fluorescent protein (shRFP). After puromycin selection, immunoblotting for Dicer protein was performed ( Figure 6E ). Densitometry showed that Dicer protein expression in shDcrA cells was reduced to 19.8% that of shRFP cells (data not shown). Moreover, expression of mature miR-181b and miR-223 in shDcrA cells was reduced 81.8 % and 83.1%, respectively, compared to shRFP cells (Supplemental Figure 3) . Similar to K562 and 293T cells, the mutant TNFAIP2 3'-UTR sequence resulted in a significant inhibition of reporter gene expression in shRFP KLE cells ( Figure 6F ). In contrast, reporter gene expression was similar for the wildtype and mutant TNFAIP2 3'-UTR constructs in cells with constitutive Dicer knock-down. Collectively, these data suggest the possibility that the TNFAIP2 3'-UTR mutation generates a binding site for an, as yet unknown, miRNA that represses translation.
DISCUSSION
In this study, we applied next generation sequencing technologies to comprehensively characterize miRNA expression, perform mutational profiling of miRNA genes, and screen for alterations in miRNA binding sites in a single patient with AML. To the best of our knowledge, this represents the first complete characterization of a "microRNAome" in a primary human cancer. We identified several novel miRNAs, some of which were differentially expressed in AML1 myeloblasts compared with normal CD34 cells. No somatic mutations of miRNA genes were identified in this leukemic genome, though several novel germline SNPs were detected.
Sequencing of the untranslated regions of all coding genes identified a single somatic mutation in a expressed gene (TNFAIP2). We provide evidence that this mutation may result in translational repression of TNFAIP2 through generation of a new miRNA binding site.
There are 940 human miRNAs in the most recent version of the Sanger miRBase database (version 15, released April 2010). It is likely that additional miRNAs remain to be discovered, especially miRNAs with tissue specific expression. High throughput sequencing of small RNA libraries offers a powerful tool to discover novel miRNAs, because it uses an unbiased approach for miRNA detection. [32] [33] [34] [35] Indeed, in the present study, we identified 7 highly expressed novel miRNAs. Of note, since we limited our analysis to the top 1,488 clusters, it is likely that additional novel miRNAs remain to be discovered that are expressed in AML or normal CD34+ cells.
A consistent finding of deep miRNA sequencing studies is the presence of isomiRs.
IsomiRs containing 5'-or 3'-extensions/deletions (1-2 nucleotides) are the most common, and likely arise from differential Drosha/Dicer processing. In addition, RNA editing enzymes, including adenosine deaminases, can generate isomiRs containing nucleotide substitutions.
Importantly, some isomiRs have been shown to alter miRNA stability or target specificity. For example, RNA editing of miR-376 producing an adenine to inosine conversion within its seed These data demonstrate the feasibility of using next generation sequencing to comprehensively characterize the miRNAome in primary human samples. In addition to miRNAs, the RNA sequencing approach provides a wealth of information about other noncoding RNAs, such as snoRNAs. Interestingly, a number of the highly expressed small RNAs mapped to unannotated regions of the genome. Studies are underway to characterize these small RNAs and assess their contribution to leukemic transformation. 4 . For personal use only. on June 10, 2017. by guest www.bloodjournal.org From to the total read counts for a specific miRNA were calculated for all miRNAs that had at least 1000 read counts between the AML1 and CD34 patient samples. Figure 5 
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